

Twenty amino acids in the PA-X C-terminal affect the virulence of influenza A viruses

Huijie Gao ^{a†}, Honglei Sun ^{a†}, Lu Qi ^a, Jinliang Wang ^a, Xin Xiong ^a, Yu Wang ^a,
Qiming He ^a, Yang Lin ^a, Weili Kong ^a, Lai-Giea Seng ^b, Juan Pu ^a, Kin-Chow Chang ^b,
Jinhua Liu ^a and Yipeng Sun ^{a,#}

^a Key Laboratory of Animal Epidemiology and Zoonosis, Ministry of Agriculture,
College of Veterinary Medicine, China Agricultural University, Beijing, China

^b School of Veterinary Medicine and Science, University of Nottingham, Sutton
Bonington Campus, United Kingdom

Running title: The role of PA-X C-terminal on influenza viruses

[#]Corresponding author. Key Laboratory of Animal Epidemiology and Zoonosis,
Ministry of Agriculture, College of Veterinary Medicine, China Agricultural
University, No. 2 Yuanmingyuan West Road, Beijing 100193, China.

Tel: +86-10-62732982; Fax: +86-10-62732982; E-mail: sypcau@163.com

[†] Huijie Gao and Honglei Sun contributed equally to this work.

Word counts: Abstract: 250; Main text: 4233

24 **Abstract**

25 The PA-X protein of influenza A virus was recently found to have arisen from
26 ribosomal frame-shift during PA translation. The X ORFs of PA-X of diverse
27 influenza A viruses can be divided into two groups according to the protein length:
28 full length PA-X (61 amino acids) and truncated PA-X (41 amino acids). A previous
29 study reported that the truncation of PA-X may be associated with the adaptation and
30 emergence of the influenza virus in host species. However, the role of the C-terminal
31 20 amino acids of PA-X in influenza A viruses is still unclear. In the present study, a
32 variety of epidemiologically important influenza A virus strains, including 2009
33 pandemic H1N1 (pH1N1), a highly pathogenic avian influenza virus of the H5N1
34 subtype, and a lowly pathogenic avian H9N2 influenza virus, served as models of
35 prevalent human and avian influenza viruses, respectively, to evaluate the impact of
36 the C-terminal 20 amino acids of PA-X on viral replication and pathogenicity. For all
37 tested viruses, those with full-length PA-X replicated more efficiently and caused
38 more apoptosis in human lung cells than truncated ones. Viruses with full length PA-X
39 were also more virulent and caused more severe inflammatory responses in mice than
40 those with truncated PA-X. The C-terminal 20 amino acids of full-length PA-X
41 accelerated nuclear accumulation of PA protein and enhanced polymerase activity of
42 pH1N1, H5N1, and H9N2 viruses. The current study addresses the role of the
43 C-terminal 20 amino acids of full length PA-X on the biological characteristics of
44 influenza A viruses.

45

46 **Importance**

47 In nature, the PA-X proteins of many types of influenza A viruses can be divided
48 into two groups according to the protein length: those with full-length PA-X and those
49 with truncated PA-X. The role of the C-terminal 20 amino acids of PA-X in current
50 epidemiologically important influenza A virus strains, including 2009 pandemic
51 H1N1 (pH1N1), highly pathogenic avian influenza H5N1 and a lowly pathogenic
52 avian H9N2 influenza viruses was demonstrated. Possible underlying processes
53 including cell death, polymerase activity, and changes in PA protein function were
54 also evaluated. The current findings suggest that the C-terminal 20 amino acids of
55 PA-X enhanced replication and pathogenicity in A549 cells and mice for pH1N1,
56 H5N1, and H9N2 viruses, which were associated with increased RNP polymerase
57 activity, apoptosis, and elevated inflammatory response. The current study assesses
58 the C-terminal 20 amino acids of PA-X as a virulence factor in the moderation of viral
59 pathogenesis and pathogenicity.

Introduction

Influenza A virus (IAV) poses a significant threat to public health and causes considerable economic losses to the livestock industry. The magnitude of pathogenicity depends on virus and host. Infections range from asymptomatic to 100% lethal. The reasons for this disparity in pathogenesis are unclear because the molecular signatures of virulence of influenza viruses are not known. IAV is an enveloped negative-strand RNA virus, and its genome comprises eight viral RNA (vRNA) segments. The genome of the influenza virus may encode 10 viral proteins in total, PB2, PB1, PA, HA, NP, NA, M1, M2, NS1, and NS2 (1, 2). Additional novel proteins have been discovered as a second or third polypeptide made from PB1 and PA mRNA. Some of these proteins, such as PB1-F2 and PA-N155, are virulence factors for the influenza virus (3-5). Recently, it has been demonstrated that segment 3 of the influenza A virus encodes not only the PA protein but also an additional novel protein, PA-X, translated as a +1 frameshift open reading frame (X-ORF) extension of a growing PA polypeptide (6). PA-X inhibits host protein synthesis and hinders the host antiviral response (6, 7). Interestingly, PA-X in the 1918 pandemic H1N1 virus reduces viral pathogenicity in mice (6).

PA-X is a fusion protein that comprises the N-terminal domain of PA (191 amino acids) and the C-terminal domain X. Comprehensive genetic analysis showed that the X ORFs of diverse influenza A viruses can be divided into two groups according to the protein length (8). Avian, equine, and human seasonal H3N2 and H1N1 influenza viruses express a full-length PA-X protein with 61 amino acids in the X domain. By contrast, some influenza A viruses, including human 2009 pandemic H1N1 (pH1N1), canine, and certain swine influenza viruses possess a TGG (Trp) to TAG (stop codon) mutation at codon 42 in the X-ORF. This mutation produces a truncated PA-X protein with 41 amino acids in the X domain. It remains unclear whether the C-terminal 20 amino acids of PA-X influence the biological characteristics of the virus.

pH1N1 influenza virus infection was the first pandemic of the 21st century and is still circulating in human and pig populations (9-11). The highly pathogenic H5N1 avian influenza viruses have undergone widespread geographic expansion among wild

90 and domestic birds. They are deadly pathogens in chickens and humans and may
91 cause a future influenza pandemic (12-14). H9N2 influenza viruses are endemic in
92 many terrestrial avian species in Asia and occasionally transmit to mammalian species
93 including humans and pigs (15-19). The PA-X ORFs of pH1N1viruses are the
94 truncated 41 amino acids in the X domain, and H5N1 and H9N2 avian influenza
95 viruses express full-length PA-X with 61 amino acids in the X domain (Fig. 1A). To
96 understand the role of the C-terminal 20 amino acids in the of PA-X in these influenza
97 viruses, the effects of the full length and truncated forms of pH1N1, H5N1, and H9N2
98 PA-X on polymerase activity, viral replication, and pathogenicity were evaluated in
99 mammalian cells and mice. Viruses with full-length PA-X here showed higher
100 polymerase activity, replication, and pathogenicity than viruses with truncated PA-X
101 in the indicated three strains.

102 **Results**

103 **Generation of full-length PA-X pH1N1 and truncated PA-X H5N1 and H9N2** 104 **viruses**

105 To assess the function of the C-terminal 20 amino acids of PA-X, sets of
106 A/Beijing/16/2009 (BJ/09, pH1N1), A/Anhui/1/2005 (AH/05, H5N1) and
107 A/chicken/Hebei/LC/2008 (HB/08, H9N2) viruses (full-length and truncated PA-X)
108 were generated using reverse genetics. A698G of PA-X ORF in pH1N1-61X and
109 G698A of PA-X ORF in H5N1-41X and H9N2-41X viruses did not affect the PA ORF
110 (Fig. 1A). Western blotting was performed to demonstrate the PA-X expression in all
111 indicated viruses infected MDCK cells (Fig. 1B). PA-X was detected in pH1N1-41X
112 (WT), pH1N1-61X, H5N1-61X (WT), H5N1-41X, H9N2-61X (WT), and H9N2-41X
113 infected cells.

114 **The C-terminal 20 amino acids of full-length PA-X played a role in viral** 115 **replication and apoptosis of influenza viruses in human lung cells**

116 Six viruses were used to infect MDCK and A549 cells at an MOI of 0.01, and the
117 supernatants were collected and titrated at 12, 24, 36, 48, 60, 72, 84, and 96 hpi. There
118 was no significant difference in viral output from MDCK cells between two forms of
119 pH1N1, H5N1, and H9N2 viruses (Fig. 2A). However, with A549 cells, the mutant

120 virus with full-length PA-X, pH1N1-61X, showed higher levels than those with
121 truncated PA-X [pH1N1-41X (WT)] from 48 hpi ($P < 0.05$) (Fig. 2B). H5N1-61X
122 (WT) with full length PA-X showed higher replication levels than H5N1-41X with
123 truncated PA-X at 84 and 96 hpi ($P < 0.05$). Full length PA-X virus, H9N2-61X (WT),
124 produced higher virus levels than with truncated PA-X, H9N2-41X, at 24, 36, and 48
125 hpi ($P < 0.05$). The data from A549 cells showed that pH1N1, H5N1, and H9N2
126 viruses with full length PA-X appeared to replicate more efficiently than
127 corresponding viruses with truncated PA-X.

128 Influenza viruses induce apoptosis and necrosis in infected cells, so causing cellular
129 and organ damage (20, 21). It has been previously shown that several viral proteins
130 (NA, M1, NS1, and PB1-F2) promote apoptosis in cells (22-26). To evaluate the
131 effect of the C-terminal 20 amino acids of full length PA-X on cell death, A549 cells
132 were infected with a panel of recombinant viruses at 1.0 MOI for 12 h. Evaluation of
133 apoptosis and necrosis by flow cytometry for annexinV⁺ and PI⁺ cells revealed that
134 pH1N1-61X virus caused more apoptosis (22.94%) than pH1N1-41X (WT) virus
135 (13.25%) ($P < 0.05$) (Fig. 2C). Similarly, H5N1-61X (WT) virus produced more
136 apoptotic cells (27.5%) than H5N1-41X virus (17.97%) and H9N2-41X virus
137 produced fewer apoptotic cells (11.82%) than H9N2-61X (WT) virus (15.17%) ($P <$
138 0.05). These results indicated that viruses with full length PA-X induced an increase in
139 apoptosis in A549 cells than those with truncated PA-X for pH1N1, H5N1 and H9N2
140 viruses.

141 **Viruses with full-length PA-X were more virulent than those with truncated** 142 **PA-X in mice**

143 To assess the pathogenicity of PA-X mutants, six-week-old BALB/c mice were
144 intranasally inoculated with each virus. Clinical signs, mortality, and weight loss were
145 monitored over 14 days. Virus-infected mice were humanely killed at 3, 5, and 7 days
146 post-infection (dpi), and lungs were collected for virus titration. For pH1N1 mutants,
147 survival curves for the 10^5 TCID₅₀ infection dose clearly showed that pH1N1-61X
148 had a higher pathogenicity than pH1N1-41X (WT). pH1N1-61X had 100% mortality
149 by 8 dpi; pH1N1-41X (WT) caused no deaths (Fig. 3A). The loss of body weight due

150 to pH1N1-61X was greater than that attributed to pH1N1-41X (WT) (Fig. 3B). The
151 pathogenicity of these viruses was further demonstrated by histopathology of lung
152 tissues collected at 5 dpi. As shown in Fig. 5A, pH1N1-61X caused more severe
153 lesions than pH1N1-41X (WT) mutants, exhibiting extensive alveolar damage and
154 cellular infiltration. Moderate interstitial pneumonia was observed in pH1N1-41X
155 (WT)-infected lungs. pH1N1-61X showed higher viral replication in the lung than
156 pH1N1-41X (WT) at 5 and 7 dpi (Fig. 4B).

157 In H5N1 mutants, H5N1-41X ($MLD_{50} = 10^{2.75}$ TCID₅₀) was attenuated in mice than
158 H5N1-61X (WT) of which MLD_{50} was $10^{2.25}$ TCID₅₀, and body weight loss of
159 H5N1-41X-infected mice were less than H5N1-61X (WT) after inoculation at 10^2
160 TCID₅₀ or 10^3 TCID₅₀ (Fig. 3D & F). The survival curves showed that H5N1-61X
161 (WT) was more pathogenic than H5N1-41X. H5N1-61X had 100% mortality by 9 dpi;
162 H5N1-41X caused 66.6% mortality after inoculation at 10^3 TCID₅₀. H5N1-61X (WT)
163 showed greater pathogenicity than H5N1-41X, with 33.3% mortality by 12 dpi;
164 H5N1-41X caused no deaths after inoculation at 10^2 TCID₅₀ (Fig. 3C & E). The titers
165 of H5N1-41X in lungs were significantly lower than those of H5N1-61X (WT) at 3
166 and 7 dpi ($P < 0.05$) in mice that had been inoculated with 10^3 TCID₅₀ of each H5N1
167 mutant (Fig. 4C). Both H5N1-61X (WT) and H5N1-41X were detected in the brains
168 and blood of mice, but H5N1-61X (WT) showed a higher replication level in the brain
169 than H5N1-41X at 5 dpi (Fig. 5D). Mice infected with H5N1-61X (WT) showed more
170 severe lesions than those infected with H5N1-41X. These infections were
171 characterized by interstitial edema, thickening of the alveolar walls, and cellular
172 infiltration (Fig. 4A).

173 As indicated in the survival curves of mice infected with H9N2 mutants at 10^6
174 TCID₅₀, H9N2-41X infection resulted in no deaths, but H9N2-61X (WT) infection
175 had 33.3% mortality (Fig. 3G). The maximum weight loss from H9N2-61X (WT) and
176 H9N2-41X infection was 12% and 5%, respectively (Fig. 3H). Lungs infected with
177 H9N2-41X virus appeared almost normal, but mild pathological changes were
178 detected in the H9N2-61X (WT) group. Some vessel walls were surrounded by
179 inflammatory cells and epithelial erosion of bronchial lining (Fig. 4A). The viral titers

180 of lungs infected with H9N2-41X were lower than those of those infected with
181 H9N2-61X (WT) at 3, 5, and 7 dpi ($P < 0.05$) (Fig. 4E). This was consistent with the
182 observed pathology.

183 Collectively, these results indicated that pH1N1, H5N1, and H9N2 viruses with
184 full-length PA-X were more pathogenic than those with truncated PA-X.

185 **Viruses with full-length PA-X caused more severe inflammatory responses in**
186 **mice than those with truncated PA-X**

187 Severe influenza virus infection in human and animal models is associated with
188 abnormally elevated pulmonary pro-inflammatory cytokine and chemokine expression
189 (27-30). To assess the effect of the C-terminal 20 amino acids of PA-X on host
190 inflammatory response, the protein levels of seven cytokines and chemokines in the
191 lungs of infected mice were measured at 3 and 5 dpi.

192 Mice infected with pH1N1-61X containing full-length PA-X virus exhibited
193 higher titers of IFN- γ , IL-1 β , IL-6, KC, TNF- α , and MIP-1 α than those with
194 pH1N1-41X (WT) at 3 and 5 dpi ($P < 0.05$) (Fig. 5A). Mice infected with H5N1-61X
195 with full-length PA-X showed higher levels of IFN- γ , IL-6, KC, TNF- α , and MIP-1 α
196 than H5N1-41X expressing truncated PA-X at 3 or 5 dpi ($P < 0.05$) (Fig. 5B). For
197 H9N2 mutants, all the chemokine and cytokine levels of H9N2-61X (WT) were
198 higher than that of H9N2-41X at 3 and 5 dpi ($P < 0.05$) (Fig. 5C).

199 These results showed that infection with pH1N1, H5N1, and H9N2 viruses carrying
200 full-length PA-X tended to elicit a more severe inflammatory response than infection
201 with truncated PA-X viruses.

202 **Full-length PA-X proteins exhibited higher polymerase activity than their**
203 **respective truncated forms**

204 The viral ribonucleoprotein (RNP) complex has been shown to be correlated with
205 viral replication and pathogenicity (31, 32). An influenza virus mini-genome assay
206 was performed on 293T cells to determine the effect of the C-terminal 20 amino acids
207 of PA-X on viral polymerase activity (33). The RNP polymerase activity from
208 pH1N1-61X expressing full length PA-X protein was 50% more pronounced than that
209 of pH1N1-41X (WT) ($P < 0.05$) (Fig. 6A). H5N1-41X showed 15% less RNP

210 polymerase activity than H5N1-61X (WT) ($P < 0.05$) (Fig. 6B). For the H9N2 virus
211 constructs, H9N2-61X (WT) RNP activity was 25% greater than that of H9N2-41X (P
212 < 0.05) (Fig. 6C). These results indicated full-length PA-X proteins had more
213 polymerase activity than their respective truncated forms of PA-X in the pH1N1,
214 H5N1, and H9N2 viruses.

215 Protein lysates derived from 293T cells transfected with RNP plasmids were
216 analyzed by Western blotting. Synonymous mutations in PA genes did not affect PA
217 protein expression for pH1N1, H5N1, or H9N2 viruses (Fig. 6D). In summary, the
218 more pronounced RNP polymerase activity of full-length PA-X in pH1N1, H5N1, and
219 H9N2 viruses was found not to be due to the differences in expression of the PA
220 protein.

221 **The C-terminal 20 amino acids of full length PA-X increased the nuclear** 222 **localization of PA protein and suppressed non-viral protein expression**

223 Accumulation of PA protein in the nucleus was found to be correlated with the
224 pathogenicity of influenza viruses in mice (34-36). The role of the C-terminal 20
225 amino acids of PA-X on PA protein accumulation in the nuclei of infected cells was
226 evaluated. A549 cells were infected with full-length and truncated PA-X pH1N1,
227 H5N1, and H9N2 viruses at 2.0 MOI. The extension of cytoplasmic accumulation of
228 PA into the nucleus was accelerated such that, at 6 hpi, more cells were infected with
229 pH1N1 or H5N1 virus with full length PA-X than with truncated. At 10 hpi, more
230 cells infected with H9N2 virus with full-length PA-X showed nuclear presence of PA
231 than cells infected with the corresponding virus with truncated PA-X (Fig. 7).

232 The PA gene plays a major role in the suppression of host protein synthesis, and this
233 role involves PA-X (6, 37). In order to determine the role of the C-terminal 20 amino
234 acids of PA-X in the suppression of host protein synthesis, the PA activity of
235 full-length PA-X was compared to that of truncated PA-X in pH1N1, H5N1, and
236 H9N2 viruses. Specifically the suppression of non-viral protein synthesis was
237 observed in 293T cells over the course of 24 h using co-transfection of pEGFP and
238 corresponding PA plasmids. There was significantly less eGFP expression in the
239 presence of H1N1-61X than in the presence of H1N1-41X (WT), and there was

significantly more in the presence of H5N1-41X PA and H9N2-41X PA than in the presence of H5N1-61X (WT) PA or H9N2-61X (WT) PA respectively (Fig. 8). In this way, full-length PA-X was found to speed up nuclear accumulation of PA protein and render PA more effective in suppressing non-viral protein expression.

Discussion

The polymerase activity, viral replication, and pathogenicity of the full length and truncated forms of PA-X were evaluated in pH1N1, H5N1, and H9N2 viruses. In all three strains viruses with full length PA-X showed more polymerase activity, replication, and pathogenicity than those with truncated PA-X.

Two forms of PA-X proteins were observed in influenza A viruses: the full-length form (61 amino acids in X-ORF) and the truncated form (41 amino acids in X-ORF) (6, 8). The two forms of PA-X in pH1N1, H5N1, and H9N2 viruses showed no significant difference in virus replication in MDCK cells. Jagger *et al.* reported similar results in MDCK cells but found no difference in single or multicycle growth kinetics of the 1918 H1N1 PA-X-deficient virus and wild type (6). However, it was here found that pH1N1, H5N1, and H9N2 viruses with full-length PA-X showed higher replication levels and caused more apoptosis in A549 cells than those with truncated PA-X. Results also showed that full-length PA-X exhibited more pathogenicity (mortality and lung pathology) than truncated PA-X in corresponding viruses. These results suggest that the mutational switch from truncated to full-length PA-X could indicate increased pathogenicity. Attention should be paid to the switch from truncated PA-X to the full-length form. Although 2009 pandemic H1N1 virus strains with full-length PA-X do not appear in nature at present, the possibility of pH1N1 acquiring full-length PA-X proteins by mutation cannot be excluded.

Results showed that pH1N1, H5N1, and H9N2 viruses with full-length PA-X had more polymerase activity than those with truncated PA-X. This was consistent with their pathogenicity. The full-length and truncated PA-X differed in the presence of 20 amino acids near the C-terminal. It is here suggested that the C-terminal 20 amino acids of the full length PA-X contribute to viral polymerase activity and pathogenicity.

There is some evidence that pathogenicity is associated with inflammatory

270 responses. Cytokine and chemokine responses, including those of IL-1 β , IFN- γ , TNF-
271 α , MIP-1 α , IL-6, MIP-2, MCP-1, KC, and IL-1 α , were found to be associated with the
272 recruitment of macrophages and neutrophils to the infected lungs, which caused acute
273 lung inflammation (30). Jagger *et al.* found that PA-X down-regulated the immune
274 response and inflammation during infection with the 1918 pandemic virus (6). In the
275 current study, in pH1N1, H5N1, and H9N2 viruses, full-length PA-X tended to elicit
276 more severe pro-inflammatory responses and more pathogenicity than truncated PA-X.
277 It is here suggested that full length PA-X could promote host inflammatory response.

278 The C-terminal 20 amino acids of full-length PA-X affected nuclear accumulation
279 of PA protein and support the suppressive role of PA protein on host protein synthesis.
280 Previous studies have reported that the level of polymerase accumulation in the nuclei
281 of infected cells is correlated with the virulence of influenza virus (34, 38). The
282 present study showed that the C-terminal 20 amino acids of full-length PA-X
283 accelerated nuclear accumulation of the PA protein in A549 cells. The increased
284 nuclear accumulation of PA was consistent with the increased virulence of pH1N1,
285 H5N1, and H9N2 viruses. In addition, PA proteins with full-length PA-X were more
286 effective in suppressing host protein expression, suggesting that the C-terminal 20
287 amino acids of full-length PA-X play a role in the suppression of host protein
288 synthesis.

289 Under natural conditions, there are changes in the length of PA-X protein of
290 influenza A viruses. For example, truncation of PA-X occurs when avian and equine
291 influenza viruses are introduced to canines, and the classic swine H1N1 viruses with
292 the truncated form of PA-X (a cluster of viruses sampled between 1985 and 2009)
293 were directly derived from those with full-length PA-X (a group of generally older
294 1930 to 2006 classic swine H1N1 viruses) (8). For these reasons, epidemiological
295 surveys should pay attention to viruses full-length PA-X, especially pH1N1 viruses.

296 **Materials and methods**

297 **Ethics statement**

298 All animal work was approved by the Beijing Association for Science and
299 Technology (approval ID SYXK [Beijing] 2007-0023) and conducted in strict

300 accordance with the Beijing Laboratory Animal Welfare and Ethics guidelines, as
301 issued by the Beijing Administration Committee of Laboratory Animals, and in
302 accordance with the China Agricultural University (CAU) Institutional Animal Care
303 and Use Committee guidelines approved by the Animal Welfare Committee of CAU.

304 **Viruses and cells**

305 A/Beijing/16/2009 (BJ/09, pH1N1), A/Anhui/1/2005 (AH/05, H5N1), and
306 A/chicken/Hebei/LC/2008 (HB/08, H9N2) viruses were described previously (39, 40).
307 Human embryonic kidney cells (293T), Madin-Darby canine kidney cells (MDCK),
308 and human pulmonary adenocarcinoma cells (A549) were maintained in Dulbecco's
309 modified Eagle's medium (DMEM; Life Technologies, Foster City, CA, U.S.)
310 supplemented with 10% fetal bovine serum (FBS; Life Technologies), 100 units/ml of
311 penicillin and 100 g/ml of streptomycin.

312 **Generation of recombinant viruses by reverse genetics**

313 All eight gene segments were amplified by reverse transcription-PCR (RT-PCR)
314 from BJ/09, AH/05, and HB/08 viruses and cloned into the dual-promoter plasmid,
315 pHW2000. The mutations were introduced into the PA gene using a Site-directed
316 QuikChange Mutagenesis Kit according to the manufacturer's instructions (Agilent,
317 Santa Clara, CA, U.S.). PCR primer sequences are available upon request. pH1N1
318 with full-length PA-X (61 amino acids), pH1N1-61X, had a stop (UAG)-to-tryptophan
319 codon (UGG) substitution at position 42 in X ORF (stop42W) without changing the
320 PA ORF (Fig. 1B). H5N1 and H9N2 viruses with truncated PA-X (41 amino acids),
321 H5N1-41X and H9N2-41X, which had a tryptophan (UGG)-to-stop codon (UAG)
322 substitution at 42 site in X ORF (W42stop) without altering the PA ORF. Rescued
323 viruses were detected using hemagglutination assays. Viral RNA was extracted and
324 analyzed by RT-PCR, and each viral segment was sequenced to confirm sequence
325 identity.

326 All experiments with live viruses and transfectants generated by reverse genetics
327 were performed in a biosafety level 3 containment laboratory approved by the
328 Ministry of Agriculture of the People's Republic of China.

329 **Viral titration and replication kinetics**

330 The 50% tissue culture infectious dose (TCID₅₀) was determined in MDCK cells
331 using 10-fold serially diluted virus inoculated at 37°C and cultured for 72 h. The
332 TCID₅₀ values were calculated using the method first described by Reed and Muench
333 (41).

334 MDCK and A549 cells were infected with virus at a multiplicity of infection
335 (MOI) of 0.01. Supernatants of the infected MDCK cells were harvested at 6, 12, 24,
336 36, 48, 60, 72, and 84 h post infection (hpi). Supernatants of the infected A549 cells
337 were harvested at 12, 24, 36, 48, 60, 72, 84, and 96 hpi. Viral titers were determined
338 in MDCK cells from the TCID₅₀. Three independent experiments were performed.

339 **Mouse infection**

340 Fifteen mice (six week-old female BALB/c; Vital River Laboratory, Beijing, China)
341 per group were anesthetized with Zoletil (tiletamine-zolazepam; Virbac S.A., Carros,
342 France; 20 µg/g) and inoculated intranasally with 50 µl of 10⁵ TCID₅₀ of pH1N1 or
343 10² or 10³ TCID₅₀ of H5N1 or 10⁶ TCID₅₀ of H9N2, diluted in phosphate-buffered
344 saline (PBS). All mice were monitored daily for 14 days; mice that lost 30% of their
345 original body weight were humanely euthanized. Three mice were euthanized 3, 5,
346 and 7 days post infection (dpi) for determination of lung virus titers, histology, and
347 cytokine levels. Lungs were collected and homogenized in 1 ml of cold PBS. Virus
348 titers were determined by TCID₅₀. The 50% minimum lethal dose (MLD₅₀) values
349 were determined by intranasally inoculating groups of three mice with 10-fold
350 dilutions of virus and were calculated by the method of Reed and Muench (41).

351 **Histopathology**

352 At 5 dpi, a portion of lung from each euthanized mouse was fixed in 10%
353 phosphate-buffered formalin and processed for paraffin embedding. Each 5 µm
354 section was stained with hematoxylin and eosin (H&E) and examined for
355 histopathological changes. Images were captured with a Zeiss Axioplan 2IE
356 epifluorescence microscope.

357 **Polymerase activity assays**

358 RNP Minigenome Luciferase Assay. Four expression plasmids housing PB2, PB1,
359 PA, and NP (125 ng each) from BJ/09, AH/05 and HB08 viruses [pH1N1-41X (WT),

360 pH1N1-61X, H5N1-61X (WT), H5N1-41X, H9N2-61X (WT), and H9N2-41X)] were
361 cloned based on the eukaryotic expression vector pcDNA3.1 and co-transfected into
362 293T cells with fire-fly luciferase reporter plasmid pYH-NS1-Luci (10 ng) and
363 internal control plasmid expressing renilla luciferase (2.5 ng). The assay was
364 performed at 37°C. At 24 hpi, cell lysate was prepared using a Dual-Luciferase
365 Reporter Assay System (Promega) and luciferase activity was measured using a
366 GloMax 96 microplate luminometer (Promega).

367 **Quantification of cytokine and chemokine protein levels in mouse lungs**

368 Levels of cytokines and chemokines, including interleukin-1 beta (IL-1 β),
369 interleukin-6 (IL-6), mouse interleukin-8 (IL-8), monocyte chemotactic protein 1
370 (MCP-1), macrophage inflammatory protein 1 alpha (MIP-1 α), tumor necrosis factor
371 alpha (TNF- α), and interferon γ (IFN- γ) in the lung were determined using a
372 cytometric bead array method (BD Cytometric BEAD Array Mouse Inflammation Kit;
373 BD Bioscience, San Diego, CA, U.S.). Briefly, 50 μ l mouse inflammation capture
374 bead suspension and 50 μ l detection reagent were added to an equal amount of sample
375 and incubated in the dark for 2 h at room temperature. Samples were later washed
376 with 1 ml wash buffer and then centrifuged at 200 \times g at room temperature for 5 min.
377 Supernatants were discarded and 300 μ l wash buffer was added. Samples were
378 analyzed on a BD FACS Array bioanalyzer (BD Bioscience). Data were analyzed
379 using BD CBA Software (BD Bioscience). Chemokine and cytokine levels were
380 recorded as pg/ml in the homogenate.

381 **Cell death assays**

382 Virus infection assays were conducted in 6-well plates. Cells were seeded at a
383 density of 1×10^6 cells/well for overnight in infection media (cell growth media with
384 1% bovine serum albumin (BSA) was used in place of FCS). Cells were then infected
385 with virus at 1.0 MOI for 12 h. Cells from the supernatant and monolayers were then
386 harvested, washed, and stained with APC labeled annexin and propidium iodide (PI)
387 (Becton Dickinson, San Jose, CA, U.S.) for 20 min. After a final wash step, cells were
388 resuspended in 100 μ l FACs wash buffer (PBS containing 3% BSA and 0.01% sodium
389 azide) and analyzed on the FACs Calibur (BD Biosciences) and BD CellQuest Pro

390 software (version 5.2.1, BD Biosciences). Cell death (apoptosis and necrosis) was
391 defined as annexin-V⁺ and PI⁺, while apoptotic cells were annexin-V⁺ only. Viable
392 cells were considered neither annexin-V nor PI positive.

393 **Western blotting**

394 Total cell protein lysates were extracted from transfected 293T cells and infected
395 MDCK cells with CA630 lysis buffer (150 mM NaCl, 1% CA630 detergent, 50 mM
396 Tris base [pH 8.0]). Cellular proteins were separated by 12% sodium dodecyl
397 sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a
398 polyvinylidene difluoride (PVDF) membrane (Amersham Biosciences, Freiburg,
399 Germany). Each PVDF membrane was blocked with 0.1% Tween 20 and 5% nonfat
400 dry milk in Tris-buffered saline and subsequently incubated with a primary antibody.
401 Primary antibodies were specific to influenza A virus PA (1:3000, GeneTex, Alton
402 Pkwy Irvine, U.S.), influenza A virus NP (diluted 1:3000, GeneTex U.S.), influenza A
403 virus PA-X (diluted 1:2000, was provided by Dr. Xiufan Liu of YangZhou University,
404 China). Secondary antibodies used here included horse radish peroxidase
405 (HRP)-conjugated anti-mouse antibody or HRP-conjugated anti-rabbit antibody
406 (diluted 1:10,000 Jackson ImmunoResearch, West Grove, U.S.), as appropriate. HRP
407 presence was detected using a Western Lightning Chemiluminescence Kit in
408 accordance with the manufacturer's protocol (Amersham Pharmacia, Freiburg,
409 Germany).

410 **Immunofluorescence**

411 A549 cells were grown on glass-bottom dishes and infected at 2.0 MOI with the
412 indicated virus. At specified points in time after infection, the cells were fixed with
413 PBS containing 4% paraformaldehyde for 20 min and permeabilized with PBS
414 containing 0.5% Triton X-100 for 30 min. After blocking with 5% BSA in PBS, the
415 cells were incubated with rabbit antisera against PA (diluted 1:400 GeneTex U.S.) at
416 room temperature for 2 h. The cells were then washed three times with PBS and
417 incubated for 1 h with fluorescein isothiocyanate (FITC)-coupled goat anti-rabbit
418 secondary antibodies (diluted 1:100, Jackson ImmunoResearch, U.S.). The cells were
419 subsequently washed three times with PBS and incubated with 4',

420 6-diamidino-2-phenylindole (DAPI) for 10 min. Cells were imaged with a laser
421 scanning confocal microscope (Leica). Localization of PA protein in the nucleus was
422 determined by counting infected cells with nuclear presence of PA (n=100). The
423 results shown represent three independent experiments.

424 **Statistical analysis**

425 The statistical analyses were performed using GraphPad Prism Software Version
426 5.00 (GraphPad Software Inc., San Diego, CA, U.S.). Comparison between two forms
427 of treatment involved two-tailed Student's t-test; multiple comparisons were carried
428 out using two-way analysis of variance (ANOVA) considering time and virus as
429 factors. Differences were considered statistically significant at $P < 0.05$. The data are
430 reported as the mean \pm standard deviation (SD).

431

432 **Acknowledgments**

433 This work was supported by the National Natural Science Foundation of China (No.
434 31302102 and No. 31430086), the National Basic Research Program (973 Program)
435 (No. 2011CB504702), a grant from the Chang Jiang Scholars Program, and a
436 Biotechnology and Biological Sciences Research Council (UK) China Partnering
437 Award.

438

439 **References**

- 440 1. **Palese P.** 1977. The genes of influenza virus. *Cell* **10**:1.
- 441 2. **Lamb R.** 1983. The influenza virus RNA segments and their encoded proteins,
442 In: Palese P, Kingsbury DW, eds. *Genetics of influenza viruses*. New York:
443 Springer-Verlag.
- 444 3. **Chen W, Calvo PA, Malide D, Gibbs J, Schubert U, Bacik I, Basta S,**
445 **O'Neill R, Schickli J, Palese P.** 2001. A novel influenza A virus mitochondrial
446 protein that induces cell death. *Nat. Med.* **7**:1306-1312.
- 447 4. **Wise HM, Foeglein A, Sun J, Dalton RM, Patel S, Howard W, Anderson**
448 **EC, Barclay WS, Digard P.** 2009. A complicated message: Identification of a
449 novel PB1-related protein translated from influenza A virus segment 2 mRNA.
450 *J. Virol.* **83**:8021-8031.
- 451 5. **Muramoto Y, Noda T, Kawakami E, Akkina R, Kawaoka Y.** 2013.
452 Identification of novel influenza A virus proteins translated from PA mRNA. *J.*
453 *Virol.* **87**:2455-2462.

- 454 6. **Jagger B, Wise H, Kash J, Walters K-A, Wills N, Xiao Y-L, Dunfee R,**
455 **Schwartzman L, Ozinsky A, Bell G.** 2012. An overlapping protein-coding
456 region in influenza A virus segment 3 modulates the host response. *Science*
457 **337**:199-204.
- 458 7. **Desmet EA, Bussey KA, Stone R, Takimoto T.** 2013. Identification of the
459 N-terminal domain of the influenza virus PA responsible for the suppression of
460 host protein synthesis. *J. Virol.* **87**:3108-3118.
- 461 8. **Shi M, Jagger BW, Wise HM, Digard P, Holmes EC, Taubenberger JK.**
462 2012. Evolutionary conservation of the PA-X open reading frame in segment 3
463 of influenza A virus. *J. Virol.* **86**:12411-12413.
- 464 9. **Trifonov V, Khiabani H, Rabadan R.** 2009. Geographic dependence,
465 surveillance, and origins of the 2009 influenza A (H1N1) virus. *N. Engl. J.*
466 *Med.* **361**:115-119.
- 467 10. **Smith GJ, Vijaykrishna D, Bahl J, Lycett SJ, Worobey M, Pybus OG, Ma**
468 **SK, Cheung CL, Raghvani J, Bhatt S, Peiris JS, Guan Y, Rambaut A.**
469 2009. Origins and evolutionary genomics of the 2009 swine-origin H1N1
470 influenza A epidemic. *Nature* **459**:1122-1125.
- 471 11. **Neumann G, Noda T, Kawaoka Y.** 2009. Emergence and pandemic potential
472 of swine-origin H1N1 influenza virus. *Nature* **459**:931-939.
- 473 12. **Duan L, Bahl J, Smith G, Wang J, Vijaykrishna D, Zhang L, Zhang J, Li**
474 **K, Fan X, Cheung C.** 2008. The development and genetic diversity of H5N1
475 influenza virus in China, 1996–2006. *Virology* **380**:243-254.
- 476 13. **Webster RG, Govorkova EA.** 2006. H5N1 influenza—continuing evolution
477 and spread. *N. Engl. J. Med.* **355**:2174-2177.
- 478 14. **Xu X, Subbarao K, Cox NJ, Guo Y.** 1999. Genetic characterization of the
479 pathogenic influenza A/Goose/Guangdong/1/96 (H5N1) virus: similarity of its
480 hemagglutinin gene to those of H5N1 viruses from the 1997 outbreaks in
481 Hong Kong. *Virology* **261**:15-19.
- 482 15. **Sun Y, Pu J, Jiang Z, Guan T, Xia Y, Xu Q, Liu L, Ma B, Tian F, Brown**
483 **EG, Liu J.** 2010. Genotypic evolution and antigenic drift of H9N2 influenza
484 viruses in China from 1994 to 2008. *Vet. Microbiol.* **146**:215-225.
- 485 16. **Xu KM, Smith GJ, Bahl J, Duan L, Tai H, Vijaykrishna D, Wang J,**
486 **Zhang JX, Li KS, Fan XH, Webster RG, Chen H, Peiris JS, Guan Y.** 2007.
487 The genesis and evolution of H9N2 influenza viruses in poultry from southern
488 China, 2000 to 2005. *J. Virol.* **81**:10389-10401.
- 489 17. **Abolnik C, Gerdes GH, Sinclair M, Ganzevoort BW, Kitching JP, Burger**
490 **CE, Romito M, Dreyer M, Swanepoel S, Cumming GS, Olivier AJ.** 2010.
491 Phylogenetic analysis of influenza A viruses (H6N8, H1N8, H4N2, H9N2,
492 H10N7) isolated from wild birds, ducks, and ostriches in South Africa from
493 2007 to 2009. *Avian. Dis.* **54**:313-322.
- 494 18. **Cong YL, Pu J, Liu QF, Wang S, Zhang GZ, Zhang XL, Fan WX, Brown**
495 **EG, Liu JH.** 2007. Antigenic and genetic characterization of H9N2 swine
496 influenza viruses in China. *J. Gen. Virol.* **88**:2035-2041.
- 497 19. **Butt AM, Siddique S, Idrees M, Tong Y.** 2010. Avian influenza A (H9N2):

- 498 computational molecular analysis and phylogenetic characterization of viral
499 surface proteins isolated between 1997 and 2009 from the human population.
500 Virol. J. 7:319.
- 501 20. **Roberts NJ, Jr., Nichols JE.** 1989. Regulation of lymphocyte proliferation
502 after influenza virus infection of human mononuclear leukocytes. J. Med.
503 Virol. 27:179-187.
- 504 21. **Tumpey TM, Lu X, Morken T, Zaki SR, Katz JM.** 2000. Depletion of
505 lymphocytes and diminished cytokine production in mice infected with a
506 highly virulent influenza A (H5N1) virus isolated from humans. J. Virol.
507 74:6105-6116.
- 508 22. **Chanturiya AN, Basanez G, Schubert U, Henklein P, Yewdell JW,
509 Zimmerberg J.** 2004. PB1-F2, an influenza A virus-encoded proapoptotic
510 mitochondrial protein, creates variably sized pores in planar lipid membranes.
511 J. Virol. 78:6304-6312.
- 512 23. **Morris SJ, Price GE, Barnett JM, Hiscox SA, Smith H, Sweet C.** 1999.
513 Role of neuraminidase in influenza virus-induced apoptosis. J. Gen. Virol. 80
514 (Pt 1):137-146.
- 515 24. **Zhirnov OP, Ksenofontov AL, Kuzmina SG, Klenk HD.** 2002. Interaction
516 of influenza A virus M1 matrix protein with caspases. Biochemistry (Mosc)
517 67:534-539.
- 518 25. **Zhirnov OP, Konakova TE, Wolff T, Klenk HD.** 2002. NS1 protein of
519 influenza A virus down-regulates apoptosis. J. Virol. 76:1617-1625.
- 520 26. **Chen W, Calvo PA, Malide D, Gibbs J, Schubert U, Bacik I, Basta S,
521 O'Neill R, Schickli J, Palese P, Henklein P, Bennink JR, Yewdell JW.** 2001.
522 A novel influenza A virus mitochondrial protein that induces cell death. Nat.
523 Med. 7:1306-1312.
- 524 27. **Bermejo-Martin JF, Martin-Loeches I, Rello J, Antón A, Almansa R, Xu
525 L, Lopez-Campos G, Pumarola T, Ran L, Ramirez P.** 2010. Host adaptive
526 immunity deficiency in severe pandemic influenza. Crit. Care. 14:R167.
- 527 28. **Hagau N, Slavcovici A, Gongnanau DN, Oltean S, Dirzu DS, Brezozski ES,
528 Maxim M, Ciuce C, Mlesnite M, Gavrus RL.** 2010. Clinical aspects and
529 cytokine response in severe H1N1 influenza A virus infection. Crit. Care.
530 14:R203.
- 531 29. **Lam WY, Yeung A, Chu I, Chan P.** 2010. Profiles of cytokine and
532 chemokine gene expression in human pulmonary epithelial cells induced by
533 human and avian influenza viruses. Virol. J. 7:344.
- 534 30. **Perrone LA, Plowden JK, García-Sastre A, Katz JM, Tumpey TM.** 2008.
535 H5N1 and 1918 pandemic influenza virus infection results in early and
536 excessive infiltration of macrophages and neutrophils in the lungs of mice.
537 PLoS. Pathog. 4:e1000115.
- 538 31. **Li C, Hatta M, Watanabe S, Neumann G, Kawaoka Y.** 2008. Compatibility
539 among polymerase subunit proteins is a restricting factor in reassortment
540 between equine H7N7 and human H3N2 influenza viruses. J. Virol.
541 82:11880-11888.

- 542 32. **Leung BW, Chen H, Brownlee GG.** 2010. Correlation between polymerase
543 activity and pathogenicity in two duck H5N1 influenza viruses suggests that
544 the polymerase contributes to pathogenicity. *Virology* **401**:96-106.
- 545 33. **Li C, Hatta M, Nidom CA, Muramoto Y, Watanabe S, Neumann G,**
546 **Kawaoka Y.** 2010. Reassortment between avian H5N1 and human H3N2
547 influenza viruses creates hybrid viruses with substantial virulence. *Proc. Natl.*
548 *Acad. Sci. U. S. A.* **107**:4687-4692.
- 549 34. **Huarte M, Falcon A, Nakaya Y, Ortin J, Garcia-Sastre A, Nieto A.** 2003.
550 Threonine 157 of influenza virus PA polymerase subunit modulates RNA
551 replication in infectious viruses. *J. Virol.* **77**:6007-6013.
- 552 35. **Song J, Feng H, Xu J, Zhao D, Shi J, Li Y, Deng G, Jiang Y, Li X, Zhu P,**
553 **Guan Y, Bu Z, Kawaoka Y, Chen H.** 2011. The PA protein directly
554 contributes to the virulence of H5N1 avian influenza viruses in domestic ducks.
555 *J. Virol.* **85**:2180-2188.
- 556 36. **Hu J, Hu Z, Mo Y, Wu Q, Cui Z, Duan Z, Huang J, Chen H, Chen Y, Gu**
557 **M, Wang X, Hu S, Liu H, Liu W, Liu X.** 2013. The PA and HA
558 gene-mediated high viral load and intense innate immune response in the brain
559 contribute to the high pathogenicity of H5N1 avian influenza virus in mallard
560 ducks. *J. Virol.* **87**:11063-11075.
- 561 37. **Desmet EA, Bussey KA, Stone R, Takimoto T.** 2013. Identification of the
562 N-Terminal Domain of the Influenza Virus PA Responsible for the
563 Suppression of Host Protein Synthesis. *J. Virol.* **87**:3108-3118.
- 564 38. **Gabriel G, Herwig A, Klenk HD.** 2008. Interaction of polymerase subunit
565 PB2 and NP with importin alpha1 is a determinant of host range of influenza A
566 virus. *PLoS. Pathog.* **4**:e11.
- 567 39. **Gu J, Xie Z, Gao Z, Liu J, Korteweg C, Ye J, Lau LT, Lu J, Zhang B,**
568 **McNutt MA, Lu M, Anderson VM, Gong E, Yu AC, Lipkin WI.** 2007.
569 H5N1 infection of the respiratory tract and beyond: a molecular pathology
570 study. *Lancet* **370**:1137-1145.
- 571 40. **Sun Y, Qin K, Wang J, Pu J, Tang Q, Hu Y, Bi Y, Zhao X, Yang H, Shu Y.**
572 2011. High genetic compatibility and increased pathogenicity of reassortants
573 derived from avian H9N2 and pandemic H1N1/2009 influenza viruses. *Proc.*
574 *Natl. Acad. Sci. U. S. A.* **108**:4164-4169.
- 575 41. **Reed LJ, Muench H.** 1938. A simple method of estimating fifty per cent
576 endpoints. *Am. J. Epidemiol.* **27**:493-497.

577


578

579


580 **Figure legends**



581
582 **Figure 1. PA-X and PA sequences of viruses used in this study.** (A) Sequences of
583 the C-terminal regions of PA-X proteins of several epidemiologically important
584 strains. (B) Western blot analysis for the detection of PA-X protein in MDCK cells
585 infected with pH1N1, H5N1, and H9N2 mutant viruses.
586



587



588

589 **Figure 2. pH1N1, H5N1, and H9N2 viruses with full-length PA-X showed more**
 590 **replication and apoptosis in A549 cells.** (A) Viral growth curves of pH1N1, H5N1.
 591 and H9N2 mutant viruses in MDCK cells and A549 cells over 84 and 96 h. Each
 592 value represents the mean of three independent experiments performed in triplicate;
 593 error bars indicate standard deviations. (B) Relative induction of cell death as
 594 determined by the detection of annexin⁺ and PI⁺ A549 cells infected with the indicated
 595 panel of viruses at a 1.0 MOI for 12 h. Representative dual-labeled quadrants of

596 bivariate fluorescence dot plots show the relative induction of apoptosis (annexin⁺)
597 and necrosis (PI⁺) in infected cells. Apoptotic cells that were positive for annexin V
598 but not PI are shown in the right lower quadrant, and those positive for PI but not
599 annexin V are shown in the left upper quadrant. Percentages shown are proportions of
600 apoptotic cells. Mock, uninfected control cells. * indicates significant differences
601 between pH1N1-61X and pH1N1-41X (WT), H5N1-41X and H5N1-61X (WT), and
602 H9N2-41X and H9N2-61X (WT).

603






Figure 3. Mortality and weight loss in mice intranasally inoculated with PA-X mutant viruses. The data show the survival (percentage) of mice infected with (A) pH1N1 PA-X, (C&E) H5N1 PA-X, and (G) H9N2 PA-X mutant viruses. The body weight of mice inoculated with (B) pH1N1 PA-X, (D&F) H5N1 PA-X, and (H) H9N2 PA-X mutant viruses was presented as percentage of the weight on the day of inoculation (day 0). Any mouse that lost more than 30% of its body weight was euthanized. The means of each group are shown, and error bars are standard deviations (SDs).

A



613




614

615 **Figure 4. (A) Histopathological changes and (B, C, D, E) viral titers in lungs of**
616 **mice infected with pH1N1, H5N1, and H9N2 mutant viruses.** Scale bars, 100 μ m.
617 The mean viral lung load \pm SD was calculated by log₁₀ TCID₅₀ determination in
618 MDCK cells. * indicates significant difference between pH1N1-61X and pH1N1-41X
619 (WT), H5N1-61X (WT) and H5N1-41X, and H9N2-61X (WT) and H9N2-41X.

620

A


■ pH1N1-41X (WT)
■ pH1N1-61X
■ Mock Infection



621

B

■ H5N1-41X
■ H5N1-61X (WT)
■ Mock Infection



622




Figure 5. Detection of cytokine and chemokine proteins in lungs of mice infected with (A) pH1N1, (B) H5N1, and (C) H9N2 PA-X mutant viruses. Mean cytokine/chemokine levels \pm SD are shown. * indicates significant differences between viruses with full length PA-X and truncated PA-X.




Figure 6. Full-length PA-X showed considerable viral polymerase activity. (A) Polymerase activity of (A) pH1N1, (B) H5N1, and (C) and H9N2 viruses with full-length PA-X and truncated PA-X, expressed as mean activity \pm SD relative to corresponding wild-type PA set at 100% from three independent experiments. (D) Western blot detections of PA, NP, and β -actin in protein lysates from 293T cells transfected with polymerase plasmids. * indicates significant differences between pH1N1-61X and pH1N1-41X (WT), H5N1-61X (WT) and H5N1-41X, and H9N2-61X (WT) and H9N2-41X.





Figure 7. Nuclear transport of PA proteins with full-length and truncated PA-X in infected cells. (A) PA protein in A549 cells infected with pH1N1-61X, pH1N1-41X (WT), H5N1-61X (WT), H5N1-41X, H9N2-61X (WT), and H9N2-41X virus at 2.0 MOI was localized by immunofluorescence at 2, 6, and 10 hpi. Nuclei were stained with DAPI. (B) At 6 hpi and 10 dpi, nuclear PA quantification was based on proportion of infected cells (n=100) with clear nuclear presence of PA. Values shown are means of the results of three independent experiments \pm SDs. *, $P < 0.05$ relative to cells infected with corresponding wild-type viruses.



649

650 **Figure 8. PAs were more effective in suppressing non-viral protein synthesis with**
651 **full length PA-X than with truncated.** (A) 293T cells were co-transfected with eGFP
652 expression plasmid and PA plasmids with full-length or truncated PA-X from pH1N1,
653 H5N1, and H9N2 viruses. (A) Fluorescence images indicative of eGFP expression at
654 24 h after transfection were captured under identical exposure conditions. (B) PA
655 protein was determined using Western blotting and anti-PA antibody. Anti- β -actin
656 antibody was used as a loading control. Control was 293T cells co-transfected with
657 eGFP expression plasmid and empty pcDNA3.1 vector.